NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO – Free Report) in a research note published on Saturday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Up 1.6 %

NURO stock opened at $4.58 on Friday. The stock’s fifty day simple moving average is $3.88 and its two-hundred day simple moving average is $3.86. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $5.56. The stock has a market cap of $9.21 million, a P/E ratio of -0.73 and a beta of 2.29.

NeuroMetrix (NASDAQ:NURO – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The business had revenue of $0.77 million during the quarter.

About NeuroMetrix

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.

Read More